Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;109:2826-2831
doi: 10.1161/01.CIR.0000132468.82942.F5
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Epstein, S. E.
Right arrow Articles by Burnett, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Epstein, S. E.
Right arrow Articles by Burnett, M. S.
Related Collections
Right arrow Angiogenesis
Right arrow Pathophysiology
Right arrow Gene expression
Right arrow Gene regulation
Right arrow Gene therapy
Right arrow Mechanism of atherosclerosis/growth factors

(Circulation. 2004;109:2826-2831.)
© 2004 American Heart Association, Inc.


Reviews: Current Perspectives

Janus Phenomenon

The Interrelated Tradeoffs Inherent in Therapies Designed to Enhance Collateral Formation and Those Designed to Inhibit Atherogenesis

Stephen E. Epstein, MD; Eugenio Stabile, MD, FESC; Timothy Kinnaird, MD; Cheol Whan Lee, MD; Leonardo Clavijo, MD; Mary Susan Burnett, PhD

From the Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington, DC.

Correspondence to Stephen E. Epstein, MD, Cardiovascular Research Institute, Washington Hospital Center, 110 Irving St NW, 4B-1, Washington, DC 20010. E-mail stephen.epstein@medstar.net


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

Enormous advances have occurred in the understanding of the molecular and cellular mechanisms responsible for both collateral development (collaterogenesis*) and atherogenesis. This advancement has been accompanied by parallel advances in therapies designed to enhance collaterals and to inhibit the development and progression of atherosclerosis. Our laboratory has been interested in both areas, and during our work, we noticed a consistent tradeoff: Whatever intervention enhanced collaterals increased atherogenesis and visa versa. We refer to this tradeoff as the Janus phenomenon.{dagger} This observation, if correct, is of more than passing interest given the many antiatherosclerotic interventions used in patients and the proangiogenic interventions being tested that may soon be used therapeutically. Therefore, if the Janus phenomenon is real, its clinical implications would be of critical importance. Equally as important, the concept might provide mechanistic insights into both atherogenesis and collaterogenesis.

Consequently, we began to track phenomena compatible with the Janus concept. Table 1 lists a few molecules for which reasonable evidence exists relating to both their atherosclerotic and collaterogenic effects and the actions of which are compatible with the Janus phenomenon.1–18 Complementary to the information contained in Table 1 are the opposite concordances displayed by different mouse strains regarding collaterogenic potential versus atherogenic susceptibility. C57BL/6 mice are susceptible to atherosclerosis and are exuberant collateral formers. Conversely, Balb/C mice are resistant to atherosclerosis and have an inferior collaterogenic capacity,19,20 suggesting that genetic determinants conveying susceptibility to atherogenesis will convey an enhanced capacity for collaterogenesis and visa versa. Therefore, the Janus phenomenon, expressing . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
A. Gianella, U. Guerrini, M. Tilenni, L. Sironi, G. Milano, E. Nobili, S. Vaga, M. C. Capogrossi, E. Tremoli, and M. Pesce
Magnetic resonance imaging of human endothelial progenitors reveals opposite effects on vascular and muscle regeneration into ischaemic tissues
Cardiovasc Res, October 31, 2009; (2009) cvp325v2.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. E. Epstein, J. Zhu, A. H. Najafi, and M. S. Burnett
Insights Into the Role of Infection in Atherogenesis and in Plaque Rupture
Circulation, June 23, 2009; 119(24): 3133 - 3141.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Zhang, D. A. Ingram, M. P. Murphy, M. R. Saadatzadeh, L. E. Mead, D. N. Prater, and J. Rehman
Release of proinflammatory mediators and expression of proinflammatory adhesion molecules by endothelial progenitor cells
Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1675 - H1682.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
S H Schirmer, F C van Nooijen, J J Piek, and N van Royen
Stimulation of collateral artery growth: travelling further down the road to clinical application
Heart, February 1, 2009; 95(3): 191 - 197.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. Rehman
An Inconvenient Truth: Recognizing Individual Differences in Arteriogenesis
Circ. Res., May 23, 2008; 102(10): 1146 - 1147.
[Full Text] [PDF]


Home page
Circ. Res.Home page
S. H. Schirmer, J. O. Fledderus, P. T.G. Bot, P. D. Moerland, I. E. Hoefer, J. Baan Jr, J. P.S. Henriques, R. J. van der Schaaf, M. M. Vis, A. J.G. Horrevoets, et al.
Interferon-{beta} Signaling Is Enhanced in Patients With Insufficient Coronary Collateral Artery Development and Inhibits Arteriogenesis in Mice
Circ. Res., May 23, 2008; 102(10): 1286 - 1294.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
A. Sukkar, J. Jenkins, J. Sanchez, and E. M. Wagner
Inhibition of CXCR2 attenuates bronchial angiogenesis in the ischemic rat lung
J Appl Physiol, May 1, 2008; 104(5): 1470 - 1475.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. Kinnaird, E. Stabile, S. Zbinden, M.-S. Burnett, and S. E. Epstein
Cardiovascular risk factors impair native collateral development and may impair efficacy of therapeutic interventions
Cardiovasc Res, May 1, 2008; 78(2): 257 - 264.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. C. Velasquez-Castano and W. R. Taylor
Angiotensin II and New Vessel Formation: Aiming for the Right Oxidative Window
Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 4 - 5.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
V. van Weel, R.E.M. Toes, L. Seghers, M.M.L. Deckers, M.R. de Vries, P.H. Eilers, J. Sipkens, A. Schepers, D. Eefting, V.W.M. van Hinsbergh, et al.
Natural Killer Cells and CD4+ T-Cells Modulate Collateral Artery Development
Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2310 - 2318.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
V. van Weel, M. de Vries, P. J. Voshol, R. E. Verloop, P. H.C. Eilers, V. W.M. van Hinsbergh, J. H. van Bockel, and P. H.A. Quax
Hypercholesterolemia Reduces Collateral Artery Growth More Dominantly Than Hyperglycemia or Insulin Resistance in Mice
Arterioscler Thromb Vasc Biol, June 1, 2006; 26(6): 1383 - 1390.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
A. Tedgui and Z. Mallat
Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
Physiol Rev, April 1, 2006; 86(2): 515 - 581.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Khurana, M. Simons, J. F. Martin, and I. C. Zachary
Role of Angiogenesis in Cardiovascular Disease: A Critical Appraisal
Circulation, September 20, 2005; 112(12): 1813 - 1824.
[Abstract] [Full Text] [PDF]